Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Syros: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness During Travel
Sponsor: Vanda Pharmaceuticals
Listed as NCT04327661, this PHASE3 trial focuses on Motion Sickness and remains completed. Sponsored by Vanda Pharmaceuticals, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Apr 2022 — Apr 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vanda Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .